Monographie - Topotecan - Stabilis 4.0

Siste oppdatering :
19/11/2024

kreft narkotika

Topotecan

Injeksjon

Oppløsningsstabilitet

Stabilitet i blandinger

Faktorer som påvirker stabiliteten

Kompatibilitet

Administrasjonsmåte

Referanser

pdf

Kjemisk struktur

Handelsnavn

Handelsnavn

Handelsnavn er veiledende og sammensetning av hjelpestoffer kan være forskjellig avhengig av land og produsent

Acumil	Mexico
Camtoop	Mexico
Cantop	India
Hycamtin	Australia, Belgia, Brasil, Canada, Chile, Colombia, Danmark, De forente arabiske emirater, Ecuador, Egypt, Finland, Frankrike, Hellas, Irland, Island, Italia, Japan, Luxembourg, Malaysia, Nederland, Norge, Polen, Portugal, Saudi-Arabia, Spania, Storbritannia, Sveits, Sverige, Tyrkia, Tyskland, Ungarn, USA, Venezuela, Østerrike
Oncotecan	Colombia, Ecuador
Potactasol	Argentina, Belgia, Norge, Romania, Tyskland
Tekan L	Tyrkia
Topodria	Colombia
Topokebir	Argentina, Peru
Toposec	Peru
Topotecan	Belgia, Canada, Colombia, Norge, Peru, Romania, Spania, Storbritannia, Tyskland
Topotel	Egypt
Toranex	Mexico
Tpopoxin	Tyrkia
Viatopin	Ungarn

Referanser

Injeksjon

Referanser : Topotecan

	Type	publikasjon
753	Labratorium	Topotecan (Topotecan Hospira®) - Summary of Product Characteristics Hospira 2016
823	Journal	Patel K, Craig SB, McBride MG, Palepu NR. Microbial inhibitory properties and stability of topotecan hydrochloride injection. Am J Health-Syst Pharm 1998 ; 55: 1584-1587.
1026	Journal	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1075	Journal	Craig SB, Bhatt UH, Patel K. Stability and compatibility of topotecan hydrochloride for injection with common infusion solutions and containers. J Pharm Biomed Anal 1997 ; 16: 199-205.
1274	Journal	Krämer I, Thiesen J. Pharmazeutische aspekte von topotecan-infusionen. TAP Pharmazeutische Zeitung 1997 ; 31: 30-33.
1423	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1425	Journal	Krämer I, Thiesen J. Stability of topotecan infusion solutions in polyvinylchloride bags and elastomeric portable infusion devices. J Oncol Pharm Practice 1999 ; 5: 75-82.
1662	Journal	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1953	Journal	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1976	Journal	Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 238-241.

Mentions Légales